AAPL 166.74 -4.13 (-2.41%)MSFT 107.48 -1.98 (-1.81%)FB 145.36 +0.33 (+0.23%)ZNGA 3.66 -0.08 (-2.01%)NVDA 147.91 -0.95 (-0.64%)WBA 79.09 -3.23 (-3.92%)GOOG 1049.8 -12.2 (-1.15%)PIH 5 -0.12 (-2.34%)
AAPL 166.74 -4.13 (-2.41%)MSFT 107.48 -1.98 (-1.81%)FB 145.36 +0.33 (+0.23%)ZNGA 3.66 -0.08 (-2.01%)NVDA 147.91 -0.95 (-0.64%)WBA 79.09 -3.23 (-3.92%)GOOG 1049.8 -12.2 (-1.15%)PIH 5 -0.12 (-2.34%)

Cash Flow ACER Quote Acer Therap

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 201420152016
NetIncome 0 0 0
Depreciation 0 0 0
DeferredIncomeT 0 0 0
StockBasedCompe 0 0 0
AccountsReceiva 0 0 0
InventoryCS 0 0 0
AccountsPayable 0 0 0
OtherWorkingCap 0 -2 0
OtherNonCashIte 1 1 0
NetCashProvided -11 -9 -14
InvestmentsInPP 0 0 0
AcquisitionsNet 0 0 1
PurchasesOfInve 0 0 0
SalesMaturities 0 0 0
PurchasesOfInta 0 0 0
OtherInvestingA 0 0 0
NetCashUsedForI 0 0 1
DebtIssued 0 0 6
DebtRepayment 0 0 0
CommonStockIssu 13 0 22
CommonStockRepu 0 0 0
DividendPaid 0 0 0
OtherFinancingA 0 0 0
NetCashProvided 13 0 27
NetChangeInCash 3 -9 14
CashAtBeginning 10 13 2
CashAtEndOfPeri 13 3 16
Acer Therapeutics Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Acer Therapeutics Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.